Vertex Pharmaceuticals (VRTX) Gross Margin (2010 - 2026)

Vertex Pharmaceuticals' Gross Margin history runs 17 years deep, the most recent figure standing at 86.85% for Q1 2026.

• In Q1 2026, Gross Margin fell 5.0% year-over-year to 86.85%; the TTM figure through Mar 2026 stood at 86.24% (up 21.0% YoY), while the FY2025 annual figure was 86.24%, up 13.0% from the prior year.
• Gross Margin was 86.85% for Q1 2026 at Vertex Pharmaceuticals, up from 85.39% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 88.76% in Q1 2023 to a low of 85.38% in Q4 2023.
• Historically, Gross Margin has averaged 86.88% across 5 years, with a median of 86.9% in 2025.
• The sharpest annual moves came in 2022 and 2023: Gross Margin jumped 79 bps in 2022, then tumbled 231 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 87.7% in 2022, then retreated by 3 bps to 85.38% in 2023, then increased by 0 bps to 85.46% in 2024, then declined by 0 bps to 85.39% in 2025, then rose by 2 bps to 86.85% in 2026.
• The last three Gross Margin figures came in at 86.85% (Q1 2026), 85.39% (Q4 2025), and 86.52% (Q3 2025), per Business Quant data.